Table 6.

Mixed Models for Treatment (Reparixin vs Placebo), and Induction of Immunosupression (1st vs 2nd ITx) in Reparixin vs Placebo. Cytokine released during the first 7 days after the 1st ITx (ATG) based on the calculated AUC was significantly higher for CXCL10 compared to the 2nd ITx (Basiliximab) in both the Reparixin and placebo groups (P < 0.05). CXCL4 release was higher after the 1st ITx compared to after the 2nd ITx only in the Reparixin group but not in the placebo group (P = 0.0154).

	Reparixin vs placebo mixed models	1st vs 2nd Tx Reparixin (paired t-test)	1st vs 2nd Tx placebo (paired t-test)
	P-value	P-value	P-value
CXCL8 [pg/ml] AUC	0.6381	0.4053	0.9252
MCP1 [pg/ml] AUC	0.7814	0.2491	0.3032
CCL3 [pg/ml] AUC	0.6708	0.2396	0.7445
CCL4 [pg/ml] AUC	0.0522	0.0154	0.0702
CXCL10 [pg/ml] AUC	0.9901	0.0194	0.0315
CXCL9 [pg/ml] AUC	0.7775	0.0516	0.4398
IL-6 [pg/ml] AUC	0.6000	0.5814	0.5948
IL-10 [pg/ml] AUC	0.7348	0.4307	0.6616
miR-375 [copies/ml] AUC	0.2054	0.6976	0.4667
miR-375/IEQ [copies in 1 ml /infusion IEQ] AUC	0.1918	0.6659	0.4262